A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)
Public ClinicalTrials.gov record NCT00420784. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response With a Prior Course of Interferon Based Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a, Pegasys®), and Ribavirin (RBV, Copegus®) in people with genotype 1 hepatitis C who have not achieved a Sustained Viral Response (SVR) with a previous treatment of interferon therapy.
Study identification
- NCT ID
- NCT00420784
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 465 participants
Conditions and interventions
Conditions
Interventions
- Telaprevir Drug
- Ribavirin Drug
- Pegylated Interferon Alfa 2a Drug
- Matching Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2007 (Type not available)
- Primary completion
- Dec 2008 (Actual)
- Completion
- Apr 2009 (Actual)
- Last update posted
- Aug 5, 2014
2007 – 2009
United States locations
- U.S. sites
- 41
- U.S. states
- 24
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Birmingham Gastroenterology Associates | Birmingham | Alabama | — | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| USC | Los Angeles | California | — | — |
| Kaiser Permanente Hepatology Research | San Diego | California | — | — |
| University of California, San Diego | San Diego | California | — | — |
| University of California San Francisco | San Francisco | California | — | — |
| University of Colorado Health Sciences Center | Denver | Colorado | — | — |
| Not listed | Englewood | Colorado | — | — |
| Not listed | Bardenton | Florida | — | — |
| University of Florida | Gainesville | Florida | — | — |
| Borland-Groover Clinic | Jacksonville | Florida | — | — |
| Mayo Clinic Jacksonville | Jacksonville | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| University Hepatitis Center at Bach & Godofsky | Sarasota | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Gulf Coast Research, LLC | Baton Rouge | Louisiana | — | — |
| Virology Treatment Center, Maine Medical Center | Portland | Maine | — | — |
| Johns Hopkins University | Baltimore | Maryland | — | — |
| Beth Isreal Deaconess Medical Center | Boston | Massachusetts | — | — |
| Henry Ford Hospital | Detroit | Michigan | — | — |
| Saint Louis University | St Louis | Missouri | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| North Shore University Hospital | Manhasset | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Durham | North Carolina | — | — |
| University Internal Medicine Associates, Inc. | Cincinnati | Ohio | — | — |
| Cleveland Clinic | Cleveland | Ohio | — | — |
| Not listed | Hershey | Pennsylvania | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Columbia Gastroenterology Associates, PA | Columbia | South Carolina | — | — |
| Memphis Gastroenterology Group | Germantown | Tennessee | — | — |
| Liver Institute at Methodist Dallas | Dallas | Texas | — | — |
| Advanced Liver Therapies | Houston | Texas | — | — |
| Alamo Medical Research | San Antonio | Texas | — | — |
| Not listed | Annandale | Virginia | — | — |
| Metropolitan Research | Fairfax | Virginia | — | — |
| Not listed | Richmond | Virginia | — | — |
| Not listed | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00420784, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 5, 2014 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00420784 live on ClinicalTrials.gov.